- €14.09bn
- €14.09bn
- €1.89bn
Europe Research Roundup: Aena, Fraport, Swedbank
European shares subdued as luxury stocks, miners weigh (updated)
Brief: Orion Expects Nubeqa Net Sales Over EUR 1 Bln By Decade's End
Orion expects cancer drug to drive 2026 sales growth, shares soar
Brief: Orion gives outlook for 2026
Brief: Orion Updates Full-Year Outlook For 2025
Orion falls as it posts Q3 miss, narrows 2025 guidance
Brief: Orion Says Tariffs Will Not Have An Impact On Co This Year
Advisory: Alert wrongly tagged to Orion SA withdrawn
Brief: Orion, Abzena Announce Exclusive Commercial License For Abzena's Antibody
Brief: Orion To Discontinue Development Of ODM-105 For Insomnia
Brief: Darolutamide Gets EU Approval for Third Prostate Cancer Indication
Brief: Orion Q2 Operating Profit EUR 104.6 Mln
Earnings Poll: Orion Oyj second quarter results due on July 18
Brief: Orion Raises Outlook For 2025
Brief: CHMP Recommends Third Indication For Darolutamide For Patients With Advanced Prostate Cancer
Brief: Orion, Glykos Announce Extension Of Research Collaboration, Licensing Agreement
Brief: Orion Signs Agreement With Shilpa Medicare
Brief: Orion And Criceto Announce License Agreement For Aporon